Dyadic International is a biotechnology company focused on developing and optimizing a proprietary platform for producing biologically-based products, including vaccines and therapeutics
The company leverages its advanced genetic engineering and expression technologies to create high-yield, cost-effective solutions for the pharmaceutical and biotech industries. Dyadic collaborates with partners to enhance drug development processes and aims to address significant health challenges through its innovative biomanufacturing capabilities. The organization is committed to advancing sustainable practices in life sciences and improving accessibility to critical medicines globally.
Companies Reporting Before The Bell • Universal Stainless (NASDAQUSAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
DYAI stock results show that Dyadic International missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
DYAI stock results show that Dyadic International missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Dyadic International (NASDAQDYAI) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Dyadic International (NASDAQDYAI) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Dyadic International (NASDAQDYAI) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement.
Dyadic International (NASDAQDYAI) brought in sales totaling $313.29 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 145.67%, resulting in a loss of $4.21 million.
